Management of emergency situations in DOAC-treated patients ‒ therapeutic options
Oliver Grottke, Aachen, Germany
Management of emergency situations in DOAC-treated patients ‒ what do we need to know?
Herbert Schöchl, Salzburg, Austria
Pharmacological characteristics and current indications of DOACs
Laura Green, London, UK
Satellite Symposium ‒ Supported by an unrestricted educational grant from Haemonetics
MANAGEMENT OF EMERGENCY SITUATIONS IN DOAC-TREATED PATIENTS: COAGULATION MONITORING AND TREATMENT OPTIONS Chair: Jakob Stensballe, Copenhagen, Denmark; Laura Green, London, UK
Clinical evaluation: study design and expectations
Alexandre Ouattara, Bordeaux, France
First evaluation of a new autotransfusion device: preclinical results
Alexandre Mansour, Rennes, France
Introduction: i-SEP and same™ technology
Patricia Forest Villegas, Lyon, France
Meet-the-expert session ‒ Supported by i-SEP
LEADING INTRAOPERATIVE AUTOTRANSFUSION Chair: Alexandre Ouattara, Bordeaux, France
The role of fibrinolysis shutdown in COVID-19
Klaus Görlinger, Munich, Germany
The role of hypercoagulability in COVID-19
Paolo Simioni, Padua, Italy
Meet-the-expert session ‒ Supported by Werfen
COVID-19-ASSOCIATED COAGULOPATHY Chairs: Paolo Simioni, Padua, Italy; Klaus Görlinger, Munich, Germany
Case-based interactive panel discussion
Kai Zacharowski, Frankfurt, Germany; Julien Pottecher, Strasbourg, France; Eric Noll, Strasbourg, France